What is the primary purpose of the new debt issuance?

The primary purpose of the new debt issuance is to refinance existing debt. Abbott intends to use the proceeds to redeem several of its outstanding notes with various maturity dates and interest rates, indicating a strategy to manage its debt profile and potentially reduce its cost of borrowing.

Are the newly issued notes secured or unsecured?

The newly issued notes and the guarantees are unsecured and unsubordinated debt obligations. They rank equally with other unsecured and unsubordinated debt but will be effectively subordinated to any future secured indebtedness of the issuer and Abbott's subsidiaries.

What existing debt is being redeemed with the proceeds from the new offering?

The proceeds are intended to redeem several existing debt tranches, including $750 million of 2.00% Notes due 2020, $596.614 million of 4.125% Notes due 2020, $818.429 million of 3.25% Notes due 2023, $81.557 million of 3.25% Notes due 2023 of St. Jude Medical, LLC, $450 million of 3.4% Notes due 2023, and $1.3 billion of 3.75% Notes due 2026.

Does this debt issuance place any significant new restrictions on Abbott?

The indenture does not contain financial covenants or restrictions on incurring additional indebtedness. However, it includes covenants that limit Abbott and certain subsidiaries from incurring secured indebtedness without equally securing the notes, and restricts sale and leaseback transactions on principal domestic properties. There are also restrictions on creating security interests on assets to secure certain listed or traded debt without securing the notes.

ABT 8-K: Material Agreements & Financial Events

Summary

Abbott Laboratories (ABT) filed an 8-K on September 28, 2018, to report on material definitive agreements and other events. The primary event is the completion of a significant debt offering by its Irish subsidiary, Abbott Ireland Financing DAC. This offering raised €3.42 billion through the issuance of unsecured, unsubordinated notes due in 2020, 2023, and 2026, with coupon rates ranging from 0.000% to 1.500%. These notes are fully guaranteed by Abbott Laboratories. The proceeds from this new debt issuance are earmarked for the redemption of several existing debt series, totaling over $3.5 billion, across various maturity dates and interest rates. This move indicates a strategic refinancing effort by Abbott to manage its debt structure and potentially lower its overall cost of borrowing. Additionally, the filing discloses the redemption of Abbott's 2.350% Notes due 2019 on September 28, 2018. This redemption, amounting to $495.5 million, was carried out in accordance with the terms of the governing indenture. Combined, these transactions demonstrate active management of Abbott's balance sheet, involving both the issuance of new debt and the retirement of existing obligations. Investors should note that while the new notes are unsecured, the indenture contains covenants restricting certain actions that could further subordinate these notes without providing equal security.

Key Highlights

1Abbott Ireland Financing DAC completed a €3.42 billion debt offering of unsecured, unsubordinated notes due 2020, 2023, and 2026.
2The new notes are fully guaranteed by Abbott Laboratories.
3Proceeds from the new debt issuance will be used to redeem multiple existing debt series, totaling over $3.5 billion.
4Abbott redeemed all $495.5 million of its outstanding 2.350% Notes due 2019 on September 28, 2018.
5The new debt offering was conducted under Regulation S, exempt from U.S. Securities Act registration.
6The indenture includes covenants that limit the incurrence of secured indebtedness and certain sale and leaseback transactions without equal and ratable security for the notes.
7The transaction reflects Abbott's active debt management and refinancing strategy.

ABBOTT LABORATORIES 8-K Report, Material Agreement (Sep 28, 2018)

Summary

Key Highlights

Frequently Asked Questions